RNA vs RARE vs JPM vs BMRN vs SRPT

For growth investors, Atrium Therapeutics, Inc.

(RNA) is the stronger pick with 70. 9% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 9x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Ultragenyx Pharmaceutical Inc. (RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 9x versus BioMarin Pharmaceutical Inc. at 30. 9x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 4. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +120. 7%, compared to -81. 0% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: JPM returned +475. 6% versus RARE's -59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc.

(BMRN) is the lower-risk stock at 0. 53β versus Sarepta Therapeutics, Inc. 's 2. 10β — meaning SRPT is approximately 297% more volatile than BMRN relative to the S&P 500. On balance sheet safety, Atrium Therapeutics, Inc. (RNA) carries a lower debt/equity ratio of 2% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Atrium Therapeutics, Inc.

(RNA) is pulling ahead at 70. 9% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Ultragenyx Pharmaceutical Inc. grew EPS 7. 3% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -411. 9% for Atrium Therapeutics, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -412. 6% for RNA. At the gross margin level — before operating expenses — RNA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 4. 5x forward P/E versus 14. 3x for JPMorgan Chase & Co. — 9. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RNA: 96. 1% to $25. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. RNA, RARE, BMRN, SRPT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +475. 6% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +475. 6%, SRPT: -16. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RNA (Healthcare) and RARE (Healthcare) and JPM (Financial Services) and BMRN (Healthcare) and SRPT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RNA is a small-cap high-growth stock; RARE is a small-cap high-growth stock; JPM is a large-cap deep-value stock; BMRN is a mid-cap quality compounder stock; SRPT is a small-cap high-growth stock. JPM pays a dividend while RNA, RARE, BMRN, SRPT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.